Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is the Immune System?01:38

What is the Immune System?

132.4K
Overview
132.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Humoral Immune Responses01:36

Humoral Immune Responses

84.1K
Overview
84.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

599
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
599

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birth.

Human vaccines & immunotherapeutics·2025
Same author

Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrio<sup>R</sup>) of Chronically HBV Infected Patients.

Journal of personalized medicine·2024
Same author

Hepatitis A virus infection.

Nature reviews. Disease primers·2023
Same author

A tribute to Professor Peter Ferenci (1948-2023).

Journal of hepatology·2023
Same author

Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries.

Journal of hepatology·2023
Same author

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Journal of hepatology·2022
Same journal

The Biology of Malaria Parasite Liver Infection.

Cold Spring Harbor perspectives in medicine·2026
Same journal

The Interaction between Diabetes Mellitus and Tuberculosis: Epidemiology, Screening, and Clinical Management.

Cold Spring Harbor perspectives in medicine·2026
Same journal

New Malaria Prevention Modalities: Long-Acting Interventions Beyond Vaccines.

Cold Spring Harbor perspectives in medicine·2026
Same journal

From Parasite to Pill: Harnessing Biology for Breakthroughs in Antimalarial Drug Discovery.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Malaria Parasite Genomics: Decentralization, Diversification, and Development Goals.

Cold Spring Harbor perspectives in medicine·2026
Same journal

Tuberculosis Infection: Diagnosis and Management.

Cold Spring Harbor perspectives in medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Immunization against Hepatitis A.

Daniel Shouval1

  • 1Liver Unit, Institute for Gastroenterology and Hepatology, Hadassah-Hebrew University Hospital, Jerusalem 91120, Israel.

Cold Spring Harbor Perspectives in Medicine
|April 18, 2018
PubMed
Summary
This summary is machine-generated.

Hepatitis A vaccines, including inactivated and live attenuated forms, offer effective protection. Ongoing research is needed for live attenuated vaccine safety and long-term immunity from single-dose inactivated vaccines.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
Selective Harvesting of Marginating-hepatic Leukocytes
06:53

Selective Harvesting of Marginating-hepatic Leukocytes

Published on: July 21, 2016

6.0K

Related Experiment Videos

Last Updated: Feb 11, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K
Selective Harvesting of Marginating-hepatic Leukocytes
06:53

Selective Harvesting of Marginating-hepatic Leukocytes

Published on: July 21, 2016

6.0K

Area of Science:

  • * Virology and Immunology
  • * Vaccine Development and Efficacy
  • * Public Health and Epidemiology

Background:

  • * Multiple formaldehyde-inactivated and live attenuated hepatitis A vaccines are currently available.
  • * Inactivated vaccines demonstrate rapid seroconversion, facilitating pre- and post-exposure prophylaxis.
  • * Universal childhood vaccination programs have successfully reduced hepatitis A incidence in endemic regions.

Purpose of the Study:

  • * To review the current landscape of hepatitis A vaccines in clinical use.
  • * To discuss the immunogenicity and prophylactic capabilities of inactivated hepatitis A vaccines.
  • * To highlight areas requiring further investigation, including fecal virus shedding from live attenuated vaccine recipients and long-term immune memory from single-dose inactivated vaccine schedules.

Main Methods:

  • * Review of existing clinical data and literature on hepatitis A vaccines.
  • * Analysis of immunogenicity, seroconversion rates, and epidemiological impact.
  • * Identification of knowledge gaps and areas for future research.

Main Results:

  • * Formaldehyde-inactivated hepatitis A vaccines show high immunogenicity and rapid seroconversion.
  • * Childhood vaccination programs utilizing these vaccines have led to significant reductions in hepatitis A incidence.
  • * Safety of inactivated vaccines is well-established, but further research is needed for attenuated vaccines and novel dosing strategies.

Conclusions:

  • * Hepatitis A vaccines are crucial tools for disease control, with inactivated vaccines proving highly effective.
  • * Further research is essential to fully understand the implications of live attenuated vaccine shedding and the durability of immunity from single-dose inactivated vaccine regimens.